GPT and glioblastoma: In newly diagnosed primary GBM, the most common AEs ≥ grade 3 of sequential monotherapy with PD-1/PD-L1 inhibitors include fatigue, pruritus, and immune-mediated AEs (diarrhea, increased alanine aminotransferase and rash), no treatment-related deaths were reported (33).